TNFSF10 and neoplasm: Multiple researchers reported the anticancer potential of human TRAIL; but, in vivo application of this gene was limited because of short half-life in the circulatory system owing to quick clearance by the kidneys and, therefore, reaching of insufficient amount of this protein to the tumor site (79, 80).